COMMUNIQUÉS West-GlobeNewswire

Motif Bio to Present Iclaprim Data at ECCMID 2018
21/02/2018
Phase 3 trial results for REVIVE-2 in patients with ABSSSI Potential cost savings opportunities with iclaprim versus vancomycin Iclaprim in vitro susceptibility data NEW YORK, Feb. 21, 2018 (GLOBE NEWSWIRE) -- Motif Bio [...]
NeuroSearch – Updated financial calendar for 2018
21/02/2018
Announcement no. 2-18 Page 1 of 1 Announcement 21 February 2018 NeuroSearch A/S (NEUR) hereby announces an update on the company’s financial calendar for 2018. 30 April 2018 Annual General Meeting 30 August 2018 Interim [...]
Basilea's CEO Ronald Scott will retire. Chief Commercial Officer David Veitch named as successor. Changes in the Board of Directors
21/02/2018
Basel, Switzerland, February 21, 2018 - Basilea Pharmaceutica Ltd. (SIX: BSLN) reported today that Chief Executive Officer Ronald Scott will retire after 18 years with the company. Basilea's Board of Directors has [...]
ProPhase Labs, Inc. Announces New Compensatory Arrangement With Chief Executive Officer and Termination of Stockholder Rights Plan
21/02/2018
DOYLESTOWN, Pa., Feb. 20, 2018 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH ) ( www.ProPhaseLabs.com ), a vertically integrated and diversified branding, marketing and technology company with deep experience in [...]
National Research Corporation Declares Quarterly Dividend
21/02/2018
Lincoln, Nebraska, Feb. 20, 2018 (GLOBE NEWSWIRE) -- National Research Corporation (NASDAQ:NRCIA and NRCIB) today announced that its Board of Directors has declared a quarterly cash dividend of $0.10 (ten cents) per [...]
Portola Pharmaceuticals Announces Results of CHMP Oral Explanations for Andexanet Alfa and Betrixaban
20/02/2018
SOUTH SAN FRANCISCO, Calif., Feb. 20, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc. ® (Nasdaq: PTLA ) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines [...]
Amarin to Report Fourth Quarter and Full Year 2017 Results and Host Conference Call on February 27th, 2018
20/02/2018
BEDMINSTER, N.J. and DUBLIN, Ireland, Feb. 20, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN ), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve [...]
AIT Therapeutics Appoints Two Senior Executives in Research and Clinical Operations
20/02/2018
Mark Rimkus Appointed VP of Clinical Affairs and Dr. Abdi Ghaffari Appointed VP of Research Appointments Add Decades of Nitric Oxide Experience to Team NEW YORK, Feb. 20, 2018 (GLOBE NEWSWIRE) -- AIT Therapeutics Inc. ( [...]
Spring Bank Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2017 Financial and Operational Results
20/02/2018
2017 highlighted by continued progress with global inarigivir clinical program for the treatment of chronic HBV and advancement of next-generation STING agonist candidate, SB 11285, towards the clinic Multiple potential [...]
Inovalon Reports Fourth Quarter and Full Year 2017 Results
20/02/2018
Fourth Quarter 2017 Highlights Fourth quarter revenue of $114.6 million, up 19% year-over-year Fourth quarter net income of $17.4 million, resulting in diluted net income of $0.12 per share, inclusive of a one-time [...]
Dova Pharmaceuticals, Inc. Announces Proposed Offering of Common Stock
20/02/2018
DURHAM, N.C., Feb. 20, 2018 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ: DOVA ), a pharmaceutical company focused on acquiring, developing and commercializing drug candidates for rare diseases where there is [...]
Quotient Limited Announces the Sale and Leaseback of its Edinburgh, Scotland Manufacturing and R&D Facility
20/02/2018
JERSEY, Channel Islands, Feb. 20, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ: QTNT ), a commercial-stage diagnostics company, today announced it has entered into definitive agreements for the sale and leaseback [...]
Ultragenyx Reports Fourth Quarter and Full Year 2017 Financial Results and Corporate Update
20/02/2018
NOVATO, Calif., Feb. 20, 2018 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE ), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today reported [...]
Avid Bioservices Announces Closing of Public Offering of Common Stock
20/02/2018
TUSTIN, Calif., Feb. 20, 2018 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO ) (NASDAQ: CDMOP ) today announced the closing of its previously announced underwritten public offering of 10,294,445 shares of its [...]
HealthEquity to Present at Investor Conferences
20/02/2018
DRAPER, Utah, Feb. 20, 2018 (GLOBE NEWSWIRE) -- HealthEquity, Inc. (NASDAQ: HQY ), the largest HSA non-bank custodian, today announced that it plans to participate at the following upcoming investor conferences: BTIG 5 [...]
Peter Miller Named Frank Baldino Bioscience CEO of the Year by Life Sciences Pennsylvania
20/02/2018
YARDLEY, Pa., Feb. 20, 2018 (GLOBE NEWSWIRE) -- Optinose (NASDAQ: OPTN ), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that CEO Peter Miller [...]
Consumer Engagement, Smarter Care Highlight Cerner Presence in Booth 1832 at HIMSS18
20/02/2018
KANSAS CITY, Mo., Feb. 20, 2018 (GLOBE NEWSWIRE) -- Cerner, a global leader in health care technology, will demonstrate its focus on the health care consumer experience and creating smarter and more efficient health [...]
Tetraphase Pharmaceuticals Enters into Exclusive Development and Commercialization Agreement with Everest Medicines for Eravacycline in China
20/02/2018
WATERTOWN, Mass., Feb. 20, 2018 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ: TTPH ), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat life-threatening [...]
Ascendis Pharma A/S Announces Proposed Public Offering of ADSs
20/02/2018
COPENHAGEN, Denmark, Feb. 20, 2018 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND ), a clinical stage biopharmaceutical company, today announced that it has commenced an underwritten public offering of $150,000, [...]

Pages